Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Acute myeloid leukemia and MDS
Phase 2/3 Trial of L-Annamycin Topoisomerase II Inhibitor in AML Remission Induction
This pivotal adaptive study evaluates L-Annamycin (a liposomal topoisomerase II inhibitor) plus Cytarabine versus placebo with Cytarabine for remission induction in adults with refractory/relapsed AML. The…
NCT06788756 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b/2 Cladribine Trial: DNA Synthesis Inhibitor in AML
This open-label study at MD Anderson Cancer Center evaluates oral cladribine (a DNA synthesis inhibitor) in combination with low dose cytarabine (a DNA synthesis inhibitor) and venetoclax (a BCL-2 inhibitor) to…
NCT07053020 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase Ia/Ib Revumenib Menin-MLL Inhibitor Trial in Pediatric Acute Leukemia
This study at M.D. Anderson evaluates the safety and efficacy of revumenib (Menin-MLL inhibitor) with daunorubicin (Topoisomerase II inhibitor), cytarabine (DNA synthesis inhibitor), and gemtuzumab ozogamicin in…
NCT07052994 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase I/II bortezomib 26S proteasome inhibitor with CPX-351 in TP53-mutated AML
This trial by the Masonic Cancer Center, University of Minnesota evaluates safety and preliminary efficacy of bortezomib (a 26S proteasome inhibitor) combined with CPX-351 (a liposomal formulation of daunorubicin and…
NCT07008638 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 Quizartinib FLT3 Inhibitor Trial in AML Maintenance
This Phase 2, multi-center, randomized, open-label trial by Daiichi Sankyo evaluates two dose levels of quizartinib, a small molecule FLT3 inhibitor, as maintenance therapy post induction and consolidation in adult…
NCT06824168 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b Venetoclax BCL-2 inhibitor trial comparing HMA versus intensive induction in AML
This therapeutic trial at The Methodist Hospital Research Institute evaluates a novel blood-based 5hmC biomarker in adults with de novo AML by comparing HMA regimens (azacitidine or decitabine plus venetoclax with…
NCT07060001 Exploratory - New trial
Uterine (endometrial) cancer
Phase 1 Pre-Operative Tirzepatide Study: Dual GIP/GLP-1 receptor agonist in obesity-driven endometrial cancer
This Phase 1 window study at UNC Lineberger Comprehensive Cancer Center evaluates tirzepatide’s potential to improve metabolic milieu and disrupt tumor biology in obese women with early-stage endometrial carcinoma.…
NCT07065552 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 1b Mosunetuzumab CD20/CD3 bispecific mAb trial in relapsed CLL/SLL patients
This pilot study evaluates mosunetuzumab administered alone or with a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib, which inhibit Bruton tyrosine kinase) in participants with chronic…
NCT07052695 Exploratory - New trial Spotlight
Ovarian cancer
Phase 3 trial: IP IMNN-001, a first‐in‐class peritoneal modulator
This randomized, adaptive, open label multicenter study sponsored by Imunon evaluates the safety and efficacy of IP IMNN-001 combined with standard neoadjuvant and adjuvant chemotherapy and maintenance therapy versus…
NCT06915025 Registrational - New trial
Ovarian cancer
Phase 2 Mirvetuximab Soravtansine ADC Targeting FOLR1 with Tubulin Inhibition
This randomized Phase 2 study evaluates the safety and efficacy of mirvetuximab soravtansine, an antibody-drug conjugate delivering DM4 (a tubulin inhibitor) to tumors expressing high folate receptor alpha in…
NCT06682988 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 1b Alpha DaRT diffusing alpha radiation emitter for pancreatic cancer
This Phase 1b multi-center study evaluates the safety and early efficacy of combining mFOLFIRINOX chemotherapy with Alpha DaRT—a device that emits targeted alpha particles—administered during the first four treatment…
NCT06698458 First-in-human - New trial
Pancreatic cancer
Phase 2: Acoustic Cluster Therapy (ultrasound-triggered microbubble enhancer) in pancreatic cancer.
This Phase 2 trial evaluates the safety and efficacy of combining Acoustic Cluster Therapy with modified FOLFIRINOX in patients with locally advanced, unresectable pancreatic cancer. Acoustic Cluster Therapy uses…
NCT06850623 Exploratory - New trial
Pancreatic cancer
Phase 1 Study of Suizenji Ultrasound-Guided HIFU Ablation for Unresectable Pancreatic Cancer
This open-label, non-randomized single-center study sponsored by SONIRE Therapeutics Inc. is evaluating the feasibility, safety, tolerability, and preliminary efficacy of Suizenji, an ultrasound-guided high-intensity…
NCT07033689 Exploratory - New trial
Lymphoma
Phase 1b Trial of NT-I7, a long-acting IL-7 cytokine boosting T-cell expansion
This Phase 1b study at Washington University School of Medicine evaluates NT-I7—an investigational long-acting human IL-7 cytokine designed to enhance T-cell proliferation—administered intramuscularly on Days 10 and…
NCT07052305 Exploratory - New trial
Lymphoma
Phase II Venetoclax BCL-2 inhibitor trial for relapsed/refractory B-cell lymphomas.
National Cancer Institute is evaluating the ViPOR regimen in patients with relapsed or refractory CD10-negative diffuse large B-cell lymphoma and high-grade B-cell lymphoma with MYC and BCL2 rearrangements. The trial…
NCT06649812 Exploratory - New trial
Lymphoma
Phase 1b Epcoritamab bispecific antibody (CD20/CD4) trial in relapsed/refractory DLBCL
This study from Memorial Sloan Kettering evaluates the safety and efficacy of a three-drug regimen for relapsed or refractory diffuse large B-cell lymphoma. Patients receive subcutaneous epcoritamab (a bispecific…
NCT07030699 Exploratory - New trial
Head and neck cancer
Phase 2 Brachytherapy Radiation Device delivering targeted radiation-induced DNA damage
This Phase 2 study by the University of Utah evaluates a reduced radiation course, using 10 fractions delivered via a brachytherapy radiation device, compared to standard radiation therapy (with chemotherapy if…
NCT07044635 Exploratory - New trial
Head and neck cancer
Phase II Sacituzumab Govitecan (TROP2-directed ADC) and Cetuximab (EGFR mAb) in Recurrent HNSCC
This Phase II trial evaluates the safety and efficacy of combining sacituzumab govitecan, a TROP2-directed antibody-drug conjugate delivering SN38, with cetuximab, an EGFR monoclonal antibody. It enrolls patients…
NCT07063212 Exploratory - New trial
Head and neck cancer
Phase II MEDI5752 CTLA-4/PD-1 bispecific mAb trial in locoregional head and neck cancer
This study, sponsored by University of Chicago, aims to assess response rate in untreated, HPV‐negative, locoregional head and neck squamous cell carcinoma using neoadjuvant therapy with volrustomig (investigational…
NCT07065630 Exploratory - New trial
Head and neck cancer
Phase II trial of BMX-001, a manganese superoxide dismutase mimetic, in head and neck cancer
This Phase II trial by NRG Oncology evaluates adding BMX-001 to standard symptom management for patients with head and neck squamous cell carcinoma undergoing chemoradiation. BMX-001 is administered subcutaneously…
NCT06532279 Exploratory - New trial
Colorectal cancer
Phase 1b Regorafenib and Lorigerlimab in Colorectal Cancer: Multi-kinase inhibitor and bispecific antibody.
This trial by MD Anderson evaluates the combination of regorafenib, a multiple kinase inhibitor, and lorigerlimab, a CD279 and CTLA4-directed bispecific monoclonal antibody, administered for up to 6 months in…
NCT07071961 Exploratory - New trial
Brain and CNS tumors
Phase 1 Study: Asciminib, a Bcr-Abl inhibitor, with optional sildenafil for brain tumors.
Researchers are evaluating single-dose asciminib, a Bcr-Abl inhibitor, alone or with sildenafil—a phosphodiesterase inhibitor—in a Phase 1 trial for patients with recurrent or progressive resectable brain tumors…
NCT07039760 Exploratory - New trial
Multiple solid tumors
Phase 1/2 MK-3120 trial of a selective receptor tyrosine kinase inhibitor.
This Phase 1/2, open-label trial conducted by Merck Sharp & Dohme LLC investigates the safety, dosing, and initial efficacy of MK-3120, a selective receptor tyrosine kinase inhibitor, in participants with advanced,…
NCT06818643 First-in-human - New trial
Multiple solid tumors
Phase 1 ABSK-011, a novel kinase inhibitor, in advanced solid tumors.
This open-label phase 1 trial enrolls patients with hepatocellular carcinoma and other advanced solid tumors who are intolerant of or have failed standard therapies. During the dose-escalation phase, participants…
NCT04906434 First-in-human - New trial
Multiple solid tumors
Phase I study of RO7673396, a RAS pathway inhibitor in advanced tumors
This study evaluates the safety and preliminary anti-tumor activity of RO7673396 in patients with advanced solid tumors harboring RAS mutations. In Stage 1, patients receive escalating doses to determine the…
NCT06884618 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 2 Momelotinib Trial: JAK1/JAK2 inhibitor for low-risk MDS anemia
This trial evaluates different momelotinib doses to optimize treatment safety, pharmacokinetics, and efficacy in reducing red blood cell transfusion needs for patients with low-risk myelodysplastic syndrome (LR-MDS)…
NCT06847867 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase I/II Study of AZD2962, an IRAK4 inhibitor, in Hematologic Neoplasms
This open-label, multicentre trial evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD2962—an IRAK4 inhibitor—administered as monotherapy in a dose-escalation…
NCT07064122 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1 zedenoleucel trial: multi-target primed allogeneic T cell therapy
This Phase 1 multicenter open-label study from Marker Therapeutics, Inc. evaluates safety and efficacy of escalating flat doses of investigational zedenoleucel, a multi-target primed allogeneic T cell therapy…
NCT06552416 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1/2 trial of Debio 1562M, novel inhibitor of aberrant leukemic signaling.
This first-in-human, open-label study evaluates Debio 1562M administered intravenously every 3 weeks to determine safety, tolerability, and optimal dosing in patients with relapsed or refractory acute myeloid…
NCT06969430 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1b Olutasidenib IDH1 inhibitor trial in IDH1-mutated myeloid cancers
This study from MD Anderson Cancer Center evaluates the safety and tolerability of olutasidenib-based combination regimens in relapsed/refractory AML or MDS/MPN with co-signaling mutations. Patients are assigned to…
NCT07032727 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.